sur AMOEBA (EPA:ALMIB)
Amoéba Secures Emergency Authorization in Italy for Biofungicide
Amoéba, a greentech firm from France, has received a 120-day emergency authorization in Italy for its biofungicide AXPERA to combat basil downy mildew. This pathogen significantly affects basil, a key Italian crop, with up to 80% of plants impacted under favorable conditions. The authorization addresses a critical need for solutions in a market where options are decreasing, especially for organic farmers who comprise a significant portion of the market.
This move is strategic for Italy's basil sector, which plays a significant role in the European market, particularly for Genovese basil used in pesto. Pesto alla Genovese's market has seen robust growth, underscoring the importance of protecting basil crops to maintain economic stability.
The authorization, supported by Italian grower associations and the Ministry of Health, allows the preventive use of AXPERA. It aligns with Amoéba's European strategy to deploy biocontrol solutions against fungal diseases pending full marketing approval.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de AMOEBA